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ABSTRACT
Background. Randomized trials have established that
patients with limited involvement of sentinel lymph node
(SLN) do not require axillary lymph node dissection (ALND).
The similar outcome in patients with B2 positive SLN with or
without additional ALND is attributed, in part, to tangential
fields (TgF) RT. We evaluated the dose distribution in the SLN
biopsy area (SLNBa) as determined intraoperatively by clips
placement for radiotherapy (RT) optimization.
Methods. This prospective study included 25 patients who
had breast conservation. Titanium clips were used intraopera-
tively to mark the SLNBa. All patients had 3D-conformal RT
using standard (STgF) or high tangential fields (HTgF). Axil-
lary levels, SLNBa, and organs at risk were contoured on a CT
scan. Dose distribution and overlap between TgF and target
volumes were analyzed.
Results. The average doses delivered to axilla levels I-III and
SLNBa were 25, 5, 2, and 33 Gy, respectively. The average
dose delivered to SLNBa was higher using HTgF with better
coverage of the axilla. Only 12 of 25 patients (48 %) had their
SLNBa completely covered by the TgF. There was no impact
of TgF size on ipsilateral lung dose. The mean heart dose
delivered using STgF was lower than HTgF.
Conclusions. In the era of SLNB, axilla and SNLBa RT
technique has to be standardized to deliver adequate dose. We
recommend the use of HTgF or direct axillary RT techniques
(such as in AMAROS trial) in patients with metastases in
SLN without ALND completion, when only TgF are expec-
ted to cure potential residual disease in the axilla.
An extensive literature, including seven randomized trials
and B32 trial update at 10 years, has established that axillary
lymph node dissection (ALND) is not required in patients
with negative sentinel lymph node biopsy (SLNB) in which
axillary recurrence is rare.1,2 SNLB represents the standard
procedure for patients with early breast cancer (BC) and
clinically node-negative (cN0). Thus, Saint-Gallen guidelines
state that ALND should not be completed in cN0 patients with
one to two macrometastatic (MAC) in the SLNs after breast-
conserving surgery (BCS) and tangential field (TgF)
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radiotherapy (RT).3 The American Society of Clinical
Oncology (ASCO) updated guidelines concluded recently
that women with one to two metastatic SLNs planning to
undergo BCS with whole breast radiation therapy (WBRT)
should not undergo ALND.4
Moreover, in the ACOSOG Z0011 trial, 6-year outcome
after BCS plus WBRT was equivalent in SLNB and ALND
patients with B2 positive SLNs. This equivalence was
attributed to the potential cure of axillary residual disease
with systemic therapy and TgF RT.5 While radiation
parameters and dose distribution in the axilla were not
reported in the initial publication, Jagsi et al. tried recently
to detail radiation treatments from the 605 available RT
report forms.5 No clear conclusions could be drawn from
the analyses on whether additional regional nodal RT was
necessary or beneficial for these patients.6 The utility of
TgF RT has been established as the standard of care. The
issue that remains outstanding relates to the benefit to
include the lymphatics.
Our study was undertaken to determine the dose distri-
bution in the sentinel lymph node biopsy area (SLNBa)
marked intraoperatively by clips. This could be helpful for
RT optimization when only TgF are used for WBRT in
patients with SLN involvement without ALND completion.
METHODS
This prospective study included 25 patients who have
undergone BCS in a single institution between April 2012
and March 2013. The Henri Mondor Breast Center Multi-
disciplinary Committee has approved the protocol.
Patients’ characteristics are presented in Table 1.
Surgery Procedure
All patients underwent BCS and SLNB procedure for
invasive BC (tumor size\3 cm, cN0). SLNB mapping was
performed using technetium-99 m-labelled human albumin
colloid particles. Blue dye was not systematically admin-
istered. SLNs were identified with a gamma detecting
probe and/or blue dyed. After SLNs removal two titanium
clips were placed to mark the location. No ALND was
performed in this study.
Radiation Therapy Technique
All patients had 3D-conformal RT. Two radiation on-
cologists contoured axilla nodal volumes, SLNBa, and
organs at risk using the RTOG contouring atlas.7 The
WBRT technique and indications followed the French
guidelines described elsewhere.8 Height of TgF was
defined individually to target the breast volume. This study
evaluated SLNBa coverage by TgF as determined intra-
operatively by clips placement. For height TgF analyses,
STgF was defined with the superior border set at 2 cm
below the humeral head, whereas HTgF consisted of a
superior border placed at the inferior edge of the humeral
head.
The SLNBa was defined as a clinical target volume
(CTVSLNB) with 5 mm in diameter surrounding the clips.
To account for position uncertainties, we defined SLNBa
planning target volume (PTVSLNB) with a 10 mm exten-
sion around the CTVSLNB (Fig. 1). Only two patients had
seroma in SLNBa with a maximum diameter of 24 and
10 mm. In both cases, clips were not displaced by the
seroma cavity. The latter was included in the PTVSLNB
(Fig. 1).
TABLE 1 Patients’ characteristics










Hormone receptor and Her 2 status
Hormone receptors ? 23






Ductal invasive carcinoma 22
Lobular invasive carcinoma 2
Carcinoma in situ 1
RT parameter
Total dose (Gy)
With boost (60–66 Gy) 21
Without boost (40–50 Gy) 4
Median delay from BCS–RT (range) (day) 43 (13–50)
Patient morphology
Mean weight (range) (kg) 67 (47–102)
Mean size (cm) 164
BSA (m2) 1.74 (1.46–2.17)
Tangential fields thickness (cm) 13.6 (9–18)
BCS breast conserving surgery; RT radiotherapy; BSA body surface
area
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FIG. 1 Topographic distribution of the clip
locations, volumes and isodoses (95 and
50 %). a Example of clips topography in the
sentinel lymph node biopsy area without
associated seroma and tangential fields
including totally the PTVSLNB. CTVSLNB
clinical target volume of the sentinel lymph
node biopsy area (in red); PTVSLNB planning
target volume of the sentinel lymph node
area (in light blue). b Example of clips
topography in the sentinel lymph node
biopsy area with associated seroma and
tangential fields including partially the
PTVSLNB. TgF were not adjusted to include
totally the SLNBa in patients with negative
SLN status. CTVSLNB clinical target volume
of the sentinel lymph node biopsy area (in
red); PTVSLNB planning target volume of the
sentinel lymph node area (in blue).
c Example of PTVSLNB and axilla levels
CTV coverage by 95 and 50 % isodoses
using standard tangential fields
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Dose-volume-histograms were analyzed according to
axilla volumes receiving 95 % (V95) or 50 % (V50) of the
prescribed dose. All values were compared according to the
use of STgF (n = 20) or HTgF (n = 5). Overlaps between
the TgF and the PTVSLNB were analyzed in three groups of
TgF-PTVSLNB overlap percentages: 100 % overlap (‘‘suit-
able group’’; PTVSLNB completely in the TgF), C50 %
overlap (‘‘partially suitable group’’; PTVSLNB partially in
the TgF), and 0–49 % overlap (‘‘unsuitable group’’; B49 %
of the PTVSLNB or completely outside the TgF; Fig. 2). Dose
distribution was calculated in each of the three groups.
Statistical Analyses
All comparisons and correlations were performed using
t tests using SPSS software. Multiples comparisons were
analyzed using an ANOVA post hoc Bonferroni. The level
of significance was stated at p \ 0.05.
RESULTS
The median number of harvested SLNs was 1 (average
1.6; range 1–6). One patient had micrometastasis (MIC;
[0.2–2 mm) and one had 1 MAC out of 4 SLNs, respec-
tively. Adjuvant systemic therapy and WBRT parameters
are presented in Table 1.
Dose and Volume Coverage
The average doses delivered to axillary levels I, II, III,
and SLNBa were 25, 5, 2, and 33 Gy, respectively.
FIG. 2 Coverage of the sentinel lymph node biopsy area by
tangential fields. Three groups of TgF-PTVSLNB overlap were
defined: 100 % overlap (‘‘suitable group’’ with PTVSLNB completely
included in the TgF), C50 % overlap (‘‘partially suitable group’’ with
PTVSLNB partially included in the TgF), and 0–49 % overlap
(‘‘unsuitable group’’ with 50 % of the PTVSLNB or completely
outside the TgF). Average dose was 46, 34, and 8 Gy, respectively in
the three groups
TABLE 2 Dose distribution in axilla levels I to III and the sentinel
lymph node biopsy area
RT parameters Targets Average (range)
Dose (Gy) Level I 25 (0–44)
Level II 5 (0–31)
Level III 2 (0–16)
PTVSLNB 33 (1–60)
D95 (Gy) Level I 5 (0–36) V95 (%) 2 (0–23)
Level II 1 (0–3) 0
Level III 1 (0–2) 0
PTVSLNB 25 (0–59) 4 (0–99)
D50 (Gy) Level I 30 (1–49) V50 (%) 47 (0–96)
Level II 4 (0–48) 4 (0–59)
Level III 2 (0–7) 1 (0–21)
PTVSLNB 33 (1–60) 65 (0–100)
RT radiotherapy; D95 dose delivered to 95 % of the target; V95
volume of the target receiving 95 % of the prescribed dose; D50 dose
delivered to 50 % of the target; V50 volume of the target receiving
50 % of the prescribed dose; PTV planning target volume; PTVSLNB
PTV of the sentinel lymph node biopsy area
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Whereas coverage of these four volumes by the 95 %
isodose was limited (0–4 %), the 50 % isodose covered 47,
4, 1, and 65 %, respectively (Table 2). The average doses
delivered to these four volumes were higher using HTgF
than STgF (38 vs. 22 Gy, p = 0.004; 11 vs. 3 Gy,
p = 0.019; 5 vs. 2 Gy, p = 0.003; 45 vs. 30 Gy,
p = 0.02), respectively (Table 3). While average D50 were
higher in HTgF versus STgF patients, no difference was
observed for D95. The results are presented in Table 3.
SLNB Area Coverage
In the STgF group (n = 20), the coverage of SLNBa by
the TgF was ‘‘suitable’’ in eight cases (40 %), ‘‘partially
suitable’’ in six cases (30 %), and ‘‘unsuitable’’ in six cases
(30 %). In the HTgF group, four and one patients were
considered ‘‘suitable’’ or ‘‘partially suitable,’’ respectively.
Finally, the SLNBa was completely covered by the TgF in
12 of 25 patients (48 %), independent of the TgF size. In
the two patients with involved SLNs, STgF were modified
as HTgF to include totally the SLNBa.
The average dose delivered to the PTVSLNB was lower
in the ‘‘unsuitable’’ (8 Gy) versus ‘‘partially suitable’’
(34 Gy) versus the ‘‘suitable’’ group (46 Gy; p = 0.01).
The difference also was significant in terms of the average
D95 (p = 0.017) and D50 (p = 0.028) delivered to the
PTVSLNB (Table 4).
Organs at Risk Analyses: Ipsilateral Lung and Heart
The percentage of ipsilateral lung volumes receiving
5 Gy (V5), 10 Gy (V10), 20 Gy (V20), and the average
dose were calculated. There was no statistical difference
between HTgF versus STgF patients for: V20 (7 vs. 6 %;
p = 0.33), V10 (13 vs. 10 %; p = 0.33), and V5 (26 vs.
20 %; p = 0.33). The mean ipsilateral lung dose using
HTgF was not significantly greater than STgF (6 vs. 5 Gy;
p = 0.2). In the left BC patients, the mean heart dose was
higher with HTgF versus STgF (2.6 vs. 1.4 Gy; p = 0.02).
TABLE 3 Dose distribution comparison in levels I to III and the
sentinel lymph node biopsy area according to tangential fields height
RT parameters Mean values p value
Axilla contents STgF HTgF
Average dose (Gy) Level I 22 38 0.004
Level II 3 11 0.019
Level III 2 5 –
PTVSLNB 30 45 0.02
D95 Level I 5 6
Level II 1 2 NS
Level III 1 1
PTVSLNB 22 33
D50 Level I 26 45 \0.001
Level II 2 12 \0.001
Level III 1 3 –
PTVSLNB 54 65 0.001
D95 dose delivered to 95 % of the target; D50 dose delivered to 50 %
of the target; PTV planning target volume; PTVSLNB PTV sentinel
lymph node biopsy area; STgF standard tangential fields; HTgF high
tangential fields; NS not significant
TABLE 4 Dose distribution comparison in axilla contents of patients groups determined regarding the overlap between the sentinel lymph node
biopsy area and tangential fields
RT parameters Axilla contents ‘‘Suitable’’ group (G I) ‘‘Partially suitable’’ group (G II) ‘‘Unsuitable’’ group (G III) p value
n 12 7 6
Average dose (Gy) Level I 31 29 8 NS
Level II 8 2 1 0.027
Level III 4 1 1 NS
PTVSLNB 46 34 8 0.01
D95 Level I 8 3 0 0.03
Level II 1 1 0 NS
Level III 1 1 0 –
PTVSLNB 42 14 1 0.017
D50 Level I 42 32 3 0.045
Level II 7 2 1 –
Level III 2 2 1 –
PTVSLNB 47 31 7 0.028
D95 dose delivered to 95 % of the target; D50 dose delivered to 50 % of the target; PTV planning target volume; PTVSLNB PTV sentinel lymph
node biopsy area; NS not significant
3762 Y. Belkacemi et al.
DISCUSSION
Our group showed recently that STgF planed for breast
RT does not allow adequate coverage of the axilla.9 These
findings are important to consider in the context of the
international guidelines on ALND avoidance when sys-
temic therapy and RT are expected to cure potential
residual disease in the axilla.1–5 However, in the past
decade, several studies have shown that STgF fails to
adequately treat levels I–II.1,9–15 In this context, two major
points on optimal regional RT technique to cover the axilla
correctly should be considered. First, recent data from
randomized trials and a meta-analysis have shown that
nodal RT increases overall survival and particularly distant
metastases free-survival.16–18 Second, RT to the axilla has
been shown as safe and equivalent to ALND in patients
with MIC in SLNB.19 These results highlight the impor-
tance of redefining adjuvant nodal RT in the SLNB era.
There is a direct relationship between prognosis and the
number of involved LNs. In patients with positive SLN, the
percentage of the SLN occupied by tumors and the number
of SLNs removed are independently predictive of non-SLN
involvement. In addition, the non-SLN involvement nega-
tively influences survival.20 Reed et al. reported that none
of 13 patients with ITCs who underwent an ALND had
additional positive nodes compared with 27 % of patients
with MIC. At 5 years, distant recurrence rates in SLN-
negative, isolated tumor cells, MIC, and MAC groups were
6, 8, 14, and 21 %, respectively. The presence of MIC in
the SLN was associated with a significantly shorter disease-
free interval than was SLN negativity (p \ 0.02).21
The RT objectives in case of axilla residual disease are
to reduce the risk of locoregional recurrence and to prevent
distant metastases from axillary sanctuary as hypothesized
by Hellman: ‘‘RT is stopping metastases at their source.’’ 22
These two objectives are highly linked together and to the
axilla contents dose. Francissen et al. reviewed 16 studies
describing patients with MAC disease in the SLN without
ALND completion.23 After 43 months of follow-up, they
observed only 24 axillary recurrences out of 3,268 (0.7 %)
among whom three received RT.23 The axillary recurrence
rate is even lower in the database study by Yi et al. with
only 0.1 % among the 1, 473 patients with MAC in the
SLN.24 Other smaller cohorts studies showed rates between
0 and 7.1 %.1 However, there is a lack of RT technique
data to conclude on the relationship between axilla un-
derdosage and local recurrence.2,5 In our study, STgF
coverage of SNLBa was complete (‘‘suitable’’ group) in
only eight cases (40 %), whereas HTgF covered the
SLNBa in four of five (80 %) patients. Indeed, the signif-
icant variations of the anatomical location of the SLNs do
not allow coverage of the SLNBa with STgF, which does
not include the LNs at highest risk of containing tumor.
Therefore, some authors suggested removing the superior-
posterior corner multileaf collimators of the TgF to cover
axilla levels.13,25,26 In our study, STgF have been modified
as HTgF to include the whole SLNBa in both patients with
metastases in the SLN.
Tumoricidal radiation dose also should be questioned.
The evaluation of the delivered doses to axilla contents in
the Z0011 study remains uncertain.5 The recent report from
Jagsi et al. based on a centralized review of 228 (out of
605) patients provided only partial results on RT technique.
Among the 185 (out of 228) patients with TgF-only treat-
ment there was sufficient data to evaluate TgF height in
142 (76.8 %) patients. Because RT parameters and nodal
volumes details were lacking, they could not evaluate the
dose distribution in the axilla. However, they showed that
direct nodal irradiation technique was mainly used in case
of multiple nodal involvements for better coverage of the
axilla compared with the HTgF technique.6
Several reports have highlighted that axillary nodal
coverage depends on the upper TgF border. Studies using
STgF showed that only approximately 50 % of level I and
20–30 % of level II nodes might receive 95 % of the
prescribed dose.10,26–28 However, several of these early
studies used conventional simulation with surgical clips as
anatomic landmarks to evaluate the dose distribution. For
example, Reed et al. showed that STgF fail to treat the
axillary level I–II anatomic volume adequately, with
approximately 50 % receiving a therapeutic dose. They
concluded that surgical clips from ALND grossly under-
estimate the level I–II axilla nodal volume and should not
be relied on for therapy planning.29
The use of HTgF in patients with MIC in the SLN is an
important issue to consider when no ALND is indicated. In
the Z0011 trial, HTgF were used in 50 and 52.6 % of
patients randomized to the ALND and SLNB arms,
respectively. Of note, only 43 (19 %) patients received
direct regional RT using C3 fields. In this small group
receiving a third field, there was a trend suggesting that
treatment with posterior axillary boost field was more
common in patients who had SLNB alone (12/21 vs. 6/22;
p = 0.0066) and those receiving nodal RT had greater
number of LNs involved (p \ 0.001).6 Axilla coverage
may be paramount to locoregional control and to decreas-
ing the risk of metastatic dissemination from residual
uncontrolled disease in the axilla. This is particularly
important to consider regarding the recent data on overall
and metastatic free-survival benefits from nodal RT in
large clinical trials.16–18
Our study was undertaken to address the question of
dose distribution and SLNBa coverage according to TgF
size. We showed that the SLNBa was completely covered
by the TgF independently from its size in only 48 % of the
patients. The average dose in the SLNBa was 33 Gy.
Breast Radiotherapy (RT) Using Tangential 3763
However, there was significantly higher delivered dose
using HTgF. The average dose is considered as nontumo-
ricidal in at least the partially suitable (34 Gy) and
unsuitable (8 Gy) groups (Table 4). To overcome the un-
derdosage of axilla, some authors have suggested tailoring
TgF to targets. Kiel et al. recommended that the cranial
field edge should be 1.2 cm below the humeral head and
that 2.5 cm of the lung be included in the breast TgF to
adequately cover the axilla.27 Schlembach et al. demon-
strated that the LNs at greatest risk are 2 cm below the
humeral head in 95 % of cases.26 Reznik et al. reported an
increase of 20–30 % of the average dose delivered to axilla
levels when using HTgF.10 Considering the same borders,
these values were lower in our earlier study in which STgF
was used in the majority of patients.9
Many authors have attempted to define the anatomical
borders by surgically marked axilla volumes and evaluated
dose distribution at each level. Krasin et al. showed that
only 1 of 25 patients received 50 Gy in the Level I of the
axilla, and no patient had an adequate coverage of the
Level II–III.11 Reed et al. showed a significant volume
difference between the anatomical and the surgically
marked axillary volumes in 18 of 50 patients undergoing
ALND with more adequate coverage of the axilla in the
latter.29 Another way to define marked axilla is to use a
sentinel clip at the caudal border in the anatomically
defined axilla. Using this procedure, Orecchia et al. showed
that only 1 of 15 patients received 40 Gy in the axilla in a
context of significant volume reduction.15
In a context of the ALND avoidance in selected patients,
the debate on the axilla underdosage by TgF has to be
addressed as the risk of non-SLNs involvement may
depend on the anatomic location of SLN and its degree of
involvement.30 The latter as determined by conventional
histology has been described as a predictive factor for
additional axillary involvement.21 Thus, as studies that
have been undertaken to quantify intraoperatively the total
tumor load in the positive SLNs showed that it is possible
to predict additional non-SLN metastasis in the axilla with
a high specificity, the authors suggested that this could be
used to guide decisions for ALND completion.30 From the
radiation oncology view, for an adequate coverage of the
axilla, the use of direct fields could be considered rather
than TgF in the patients with SLN involvement without
further ALND.19
CONCLUSIONS
In patients undergoing BCS followed by WBRT, STgF
provide a limited coverage of the axilla contents and
deliver a nontumoricidal dose to potential axillary residual
disease. The RT technique to deliver adequate dose to
axilla and SLNBa has to be standardized with the use of
HTgF or direct fields as described in AMAROS trial.19
This is true, insofar as we have: only limited follow-up in
the SLNB trials without RT technique details, no clear
tumoricidal dose level for residual disease, and uncertain-
ties on the disease in the remained axilla non-SLN.
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